AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 43.38 |
|---|---|
| Change | -0.470 1.083% |
| 52 W H/L (in USD) | 36.480/25.170 |
| EBITDA (in USD) | 281.121M |
| PE Ratio | 23.44 |
| Volume | 583826 |
| Diluted Eps TTM | 1.43 |
| Total Assets (in USD) | 2530.255M |
|---|---|
| Total Liabilities (in USD) | 710.96M |
| Revenue TTM (in USD) | 1475.899M |
| Cash (in USD) | 1119.776M |
| Market Cap (in USD) | 5,586.106 M |
| Revenue Per Share TTM | 8.961 |
| Gross Profit TTM (in USD) | 1279.442M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Employees: 2050
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Richard F. Pops | Chairman & CEO | 1962 |
| 2. | Mr. Iain Michael Brown | Sr. VP & CFO | 1969 |
| 3. | Mr. Blair C. Jackson | Exec. VP & COO | 1973 |
| 4. | Mr. David Joseph Gaffin | Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec. | 1972 |
| 5. | Dr. Craig C. Hopkinson M.D. | Exec. VP of R&D and Chief Medical Officer | 1968 |
| 6. | Dr. Floyd E. Bloom M.D. | Founder | 1937 |
| 7. | Mr. Thomas Harvey | Chief Information Officer & Sr. VP of IT | NA |
| 8. | Ms. Sandra Coombs | Sr. VP of Corp. Affairs & Investor Relations | NA |
| 9. | Mr. Michael J. Landine | Sr. VP of Corp. Devel. & Chief Risk Officer | 1954 |
| 10. | Mr. Stephen Schiavo | Sr. VP of HR | NA |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ZTS
Zoetis Inc |
+0.834 1.049% | 79.54 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
|
MKKGY
Merck KGaA ADR |
-0.540 1.671% | 32.09 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
0.000 0.000% | 163.71 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
GALDY
GALDERMA GROUP AG |
-0.065 0.160% | 40.64 | 74.210 | 41.667 | 8.636 | 5.553 | 9.151 | 42.220 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | 291.45M | 443.75M | 421.519M | -167.304M | -39.306M |
| Minority Interest | - | - | - | - | - |
| Net Income | 241.664M | 367.07M | 355.757M | -158.267M | -48.169M |
| Selling General Administrative | 701.522M | 199.024M | 199.597M | 605.747M | 560.977M |
| Gross Profit | 1273.842M | 1312.301M | 1410.368M | 893.687M | 569.838M |
| Reconciled Depreciation | 27.165M | 28.533M | 74.927M | 36.363M | 78.652M |
| Ebit | 303.727M | 466.328M | 444.551M | -142.265M | -26.66M |
| Ebitda | 330.892M | 494.861M | 519.478M | -96.151M | 11.488M |
| Depreciation And Amortization | 27.165M | 28.533M | 74.927M | 46.114M | 38.148M |
| Operating Income | 253.956M | 420.636M | 414.122M | -142.265M | -26.66M |
| Other Operating Expenses | 1221.943M | 1136.996M | 1249.283M | 1254.06M | 1203.038M |
| Interest Expense | 12.277M | 22.578M | 23.032M | 13.04M | 11.219M |
| Tax Provision | 49.786M | 71.612M | -97.638M | -9.037M | 8.863M |
| Interest Income | 45.304M | 42.45M | 30.854M | 7.629M | 2.408M |
| Net Interest Income | 33.027M | 19.872M | 7.822M | -5.411M | -8.811M |
| Income Tax Expense | 49.786M | 71.612M | -97.638M | -9.037M | 8.863M |
| Total Revenue | 1475.899M | 1557.632M | 1663.405M | 1111.795M | 1173.751M |
| Total Operating Expenses | 1019.886M | 891.665M | 996.246M | 1035.952M | 599.125M |
| Cost Of Revenue | 202.057M | 245.331M | 253.037M | 218.108M | 603.913M |
| Total Other Income Expense Net | 37.494M | 23.114M | 7.397M | -25.039M | -12.646M |
| Net Income From Continuing Ops | 241.664M | 372.138M | 519.157M | -158.267M | -48.169M |
| Net Income Applicable To Common Shares | - | - | - | -158.267M | -48.169M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 2530.255M | 2055.567M | 2136.223M | 1963.978M | 2024.484M |
| Intangible Assets | 83.842M | 0.89M | 1.991M | 37.68M | 74.043M |
| Other Current Assets | 79.09M | 91.282M | 98.166M | 43.527M | 48.967M |
| Total Liab | 710.96M | 590.59M | 933.537M | 920.225M | 911.9M |
| Total Stockholder Equity | 1819.295M | 1464.977M | 1202.686M | 1043.753M | 1112.584M |
| Other Current Liab | 428.741M | 412.154M | 444.299M | 455.083M | 406.226M |
| Common Stock | 1.81M | 1.767M | 1.726M | 1.69M | 1.658M |
| Capital Stock | 1.81M | 1.767M | 1.726M | 1.69M | 1.658M |
| Retained Earnings | -734.794M | -976.458M | -1343.528M | -1699.285M | -1541.018M |
| Good Will | 83.842M | 83.027M | 83.027M | 92.873M | 92.873M |
| Other Assets | 936.604M | - | 0M | 122.393M | 224.915M |
| Cash | 1119.776M | 291.146M | 457.469M | 292.473M | 337.544M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 543.437M | 465.199M | 515.678M | 497.742M | 471.286M |
| Current Deferred Revenue | - | 1.249M | 2.73M | 6.816M | 6.339M |
| Net Debt | -1049.777M | -215.608M | -166.739M | 0.797M | -41.74M |
| Short Term Debt | 6.746M | 6.166M | 3M | 3M | 3M |
| Short Long Term Debt | - | - | 3M | 3M | 3M |
| Short Long Term Debt Total | 69.999M | 75.538M | 290.73M | 293.27M | 295.804M |
| Other Stockholder Equity | 2554.379M | 2441.635M | 2547.598M | 2752.237M | 2655.667M |
| Property Plant Equipment | - | - | - | 325.361M | 341.054M |
| Total Current Assets | 1929.161M | 1415.355M | 1431.133M | 1261.916M | 1291.599M |
| Long Term Investments | 0.145M | 73.148M | 39.887M | 131.61M | 229.43M |
| Short Term Investments | 199.645M | 460.522M | 316.022M | 315.992M | 198.767M |
| Net Receivables | 334.025M | 389.518M | 333.183M | 296.896M | 326.556M |
| Long Term Debt | - | - | 287.73M | 290.27M | 292.804M |
| Inventory | 196.625M | 182.887M | 186.406M | 181.418M | 150.335M |
| Accounts Payable | 107.95M | 45.63M | 65.649M | 32.843M | 55.721M |
| Accumulated Other Comprehensive Income | -2.1M | -1.967M | -3.11M | -10.889M | -3.723M |
| Non Currrent Assets Other | 49.099M | 16.503M | 157.354M | -1.064M | -86.348M |
| Non Current Assets Total | 601.094M | 640.212M | 705.09M | 702.062M | 732.885M |
| Capital Lease Obligations | 69.999M | 75.538M | 81.455M | 105.551M | 120.402M |
| Long Term Debt Total | - | - | - | 290.27M | 292.804M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 333.123M | -111.308M | 102.079M | -28.044M | -45.408M |
| Total Cashflows From Investing Activities | 295.497M | -111.308M | 53.357M | -64.541M | -66.204M |
| Total Cash From Financing Activities | 12.379M | -494.139M | -289.714M | -1.574M | 29.072M |
| Net Income | 241.664M | 367.07M | 355.757M | -158.267M | -48.169M |
| Change In Cash | 828.63M | -166.323M | 164.996M | -45.071M | 64.583M |
| Begin Period Cash Flow | 291.146M | 457.469M | 292.473M | 337.544M | 272.961M |
| End Period Cash Flow | 1119.776M | 291.146M | 457.469M | 292.473M | 337.544M |
| Total Cash From Operating Activities | 520.754M | 439.124M | 401.353M | 21.044M | 101.715M |
| Depreciation | 27.165M | 28.533M | 74.927M | 77.862M | 78.652M |
| Other Cashflows From Investing Activities | 0.296M | 0.461M | 0.354M | 1.758M | 7.224M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -14.061M | 3.091M | -2.712M | -31.021M | -24.769M |
| Sale Purchase Of Stock | -31.032M | -200.282M | -28.474M | 19.63M | 25.319M |
| Other Cashflows From Financing Activities | 0.012M | -2.065M | -275M | 1.426M | 31.322M |
| Capital Expenditures | 40.42M | 33.484M | 48.048M | 38.255M | 29.02M |
| Change In Working Capital | 119.124M | -98.15M | -36.663M | 12.709M | -25.548M |
| Other Non Cash Items | 104.027M | 4.512M | 6.329M | 27.281M | 4.077M |
| Free Cash Flow | 480.334M | 405.64M | 353.305M | -17.211M | 72.695M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core S&P Small-Cap ETF | 2 months ago | 9919327 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 5281484 |
| 3. | Avantis US Small Cap Value ETF | 2 months ago | 4262975 |
| 4. | iShares Russell 2000 ETF | 2 months ago | 3933419 |
| 5. | Vanguard Small Cap Index | 2 months ago | 3848013 |
| 6. | T. Rowe Price US Mid-Cap Value Equity | 5 months ago | 3736893 |
| 7. | State Street® SPDR® S&P® Biotech ETF | 2 months ago | 3192526 |
| 8. | First Trust NYSE Arca Biotech ETF | 2 months ago | 2719064 |
| 9. | Vanguard Small Cap Growth Index Inv | 2 months ago | 2155847 |
| 10. | JPMorgan Mid Cap Growth I | 3 months ago | 2094585 |
| 11. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 1846682 |
| 12. | T. Rowe Price Mid-Cap Value | 2 months ago | 1776566 |
| 13. | JPM US Mid Cap Growth-Composite | 2 months ago | 1775924 |
| 14. | Vanguard Capital Opportunity Inv | 5 months ago | 1733250 |
| 15. | Fidelity Small Cap Index | 4 months ago | 1570250 |
| 16. | State Street SPDR Port S&P 600 Sm CpETF | 2 months ago | 1495043 |
| 17. | iShares S&P Small-Cap 600 Growth ETF | 2 months ago | 1424594 |
| 18. | iShares Biotechnology ETF | 2 months ago | 1219192 |
| 19. | T. Rowe Price U.S. Mid-Cap Val Eq Tr-D | 2 months ago | 1076038 |
| 20. | Vanguard Tax-Managed Small Cap Adm | 2 months ago | 1075769 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | T. Rowe Price Associates, Inc. | 8 months ago | 10238357 |
| 2. | Baker Bros Advisors LP | 5 months ago | 10012267 |
| 3. | State Street Corp | 8 months ago | 8540351 |
| 4. | JPMorgan Chase & Co | 8 months ago | 7856340 |
| 5. | Renaissance Technologies Corp | 5 months ago | 6668028 |
| 6. | Nuveen, LLC | 5 months ago | 2427028 |
| 7. | The Goldman Sachs Group Inc | 5 months ago | 2267588 |
| 8. | BlackRock Inc | 8 months ago | 27972078 |
| 9. | Vanguard Group Inc | 5 months ago | 18007364 |
| 10. | American Century Companies Inc | 5 months ago | 5956824 |
| 11. | Dimensional Fund Advisors, Inc. | 5 months ago | 4412783 |
| 12. | Geode Capital Management, LLC | 5 months ago | 4080776 |
| 13. | COMMODORE CAPITAL LP | 5 months ago | 3550000 |
| 14. | Wellington Management Company LLP | 5 months ago | 3020442 |
| 15. | PRIMECAP Management Company | 5 months ago | 2564300 |
| 16. | Charles Schwab Investment Management Inc | 5 months ago | 2152756 |
| 17. | Deep Track Capital, LP | 5 months ago | 2000000 |
| 18. | NORGES BANK | 5 months ago | 1945734 |
| 19. | Loomis, Sayles & Company LP | 5 months ago | 1902522 |
| 20. | Northern Trust Corp | 8 months ago | 1766180 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...